Navigation Links
Psychemedics Corporation Announces Sales & Marketing Agreement With Bupa in UK
Date:5/19/2009

ACTON, Mass., May 19 /PRNewswire-FirstCall/ -- Psychemedics Corporation (Nasdaq: PMD) today announced that it has signed a sales and marketing agreement with leading international health and care organization Bupa, to market the patented Psychemedics hair analysis drug test in the UK.

Around one in three adults between the ages of 16 and 59 living in England and Wales admit to illegal drug use at some time(1) and many firms, especially where workplace safety is critical, have a legal obligation to prevent staff from attempting to perform tasks under the influence of drugs or alcohol.

Bupa Wellness is the pioneer of health screening in the UK and offers a range of preventive services to keep employees in the best of health and at work. The company looks after thousands of employees working in many of the UK's leading companies through a range of occupational health, risk assessment, sickness absence reduction and wellness promotion services.

Bupa Wellness helps employers concerned about the impact of drugs and alcohol in their business and can assist with the development of specific policies as well as screening, whether pre-employment, random or post incident related.

Bupa Wellness currently offers urine and oral fluid testing. The patented Psychemedics hair analysis test for drug abuse will be added to Bupa's range of services. Last year, Bupa tested tens of thousands of employees for drugs and alcohol and was requested to attend client workplaces following a drug or alcohol related incident or concern around 100 times per month on average.

Raymond C. Kubacki, Chairman and Chief Executive Officer of Psychemedics, stated, "We are extremely pleased to be working with Bupa Wellness, the highest quality provider of drug and alcohol screening in the UK. We view this as the perfect match since we provide the highest quality and most cost effective drug test available. By offering employers a true one-stop shop for drug and alcohol screening from policy development to rehabilitation, Bupa Wellness can capitalize on the rapidly developing growth opportunities in the UK."

Dr Jenny Leeser, Clinical Director Occupational Health for Bupa Wellness commented: "The Psychemedics hair test provides a key addition to the comprehensive drug and alcohol screening programs we already offer our clients. As the world's leader in drug testing using hair analysis, Psychemedics's patented method provides the highest quality drug test available. We are very pleased that we will now be able to offer this test to our clients, thus further helping them to establish and maintain a drug-free workplace."

NOTES TO EDITORS

(1) European Monitoring Centre for Drugs and Drug Addiction 2005

For further information please contact:

Raymond C. Kubacki

Chairman, President and CEO

Psychemedics

Tel: +01 (978) 206-8220

About Psychemedics

Psychemedics Corporation is the world's largest provider of testing for drugs of abuse using hair analysis with thousands of corporations relying on the patented Psychemedics drug testing services. Psychemedics's clients include over 10% of the Fortune 500, some of the largest police departments in America and Federal Reserve Banks.

The Psychemedics web site is www.drugtestwithhair.com

OR

Joanne Hudson

Bupa Corporate Communications

Tel: +44 (0) 20 7656 2273

Email: hudsojoa@bupa.com

About Bupa

Bupa is the UK market leader in health and care with a strong international presence. Established in 1947, it has over 10 million customers in more than 190 countries and over 52,000 employees. Its main interests are health insurance, care homes for older people and young disabled, health assessments, workplace health services. Bupa Travel offers a bespoke travel insurance service. Sanitas in Spain, MBF, HBA, Mutual Community in Australia and DCA Agedcare in Australia and New Zealand, IHI in Denmark and Health Dialog in the US are all part of the Bupa Group which also has centres in Hong-Kong, Thailand and Saudi Arabia. Bupa is a company limited by guarantee and does not have a share capital. As a result, it can focus on its customers, helping them to live longer, healthier lives and can reinvest all of its profits to do this - this is the dividend that Bupa provides.

The Bupa web site is www.bupa.com

Cautionary Statement for purposes of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995: From time to time, information provided by Psychemedics may contain forward-looking information that involves risks and uncertainties. In particular, statements contained in this release that are not historical facts (including but not limited to statements concerning earnings, earnings per share, revenues, dividends, future business, new accounts, customer base, market share, test volume and sales and marketing strategies) may be "forward looking" statements. Actual results may differ from those stated in any forward-looking statements. Factors that may cause such differences include but are not limited to risks associated with the expansion of the Company's sales and marketing network, development of markets for new products and services offered, the economic health of principal customers of the Company, government regulation, including but not limited to FDA regulations, competition and general economic conditions and other factors disclosed in the Company's filings with the Securities and Exchange Commission.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Raymond C. Kubacki, Jr.

https://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=49521


'/>"/>
SOURCE Psychemedics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Psychemedics Corporation Joins Accenture in Co-Sponsoring Innovative Chief Talent Officer Book
2. Jennifer Chmieleski Joins Psychemedics Corporation as Top Financial Officer
3. Psychemedics Corporation Announces Year End Results Record Annual and Quarterly Revenue
4. Psychemedics Corporation Announces First Quarter Results
5. Psychemedics Corporation Announces Second Quarter Results
6. Raymond J. Ruddy Joins Psychemedics Corporation As Top Financial Officer
7. Psychemedics Corporation Announces Third Quarter Results
8. Psychemedics Corporation Announces First Quarter Results
9. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
10. Brooke Franchise Corporation Announces Selected July Results
11. MedThink Communications Retained by NanoBio Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... FL (PRWEB) , ... February 17, 2017 , ... ... software tools that allow for the electronic prescribing of controlled and non-controlled substances ... , Ninety percent of pharmacies in the United States now accept electronic prescriptions, ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's mental functions, ... each and every seminar, session and class she offers. At the International ... which help energize creativity, focus mental functions, enhance athletic focus and skill sets, ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting attended ... all facets of clinical trial planning and management. Pharmica discussed the importance of ... In addition, attendees stopping by Pharmica’s booth were able to demo its cloud-based ...
(Date:2/17/2017)... ... 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial Hospital ... the Hospital Readmission Reduction Program (HRRP), the return of a patient to the hospital ... the nation. While many providers are struggling to leverage limited resources and technology, Onslow ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... Cryoablation, Electrical, Endometrial Hydrothermal, Laser/Light, Microwave, Radiofrequency, Ultrasound, Cardiovascular, Gynaecology, ... expected to grow at a CAGR of 9.4% from 2017-2022 and ... at a CAGR of 9.5% from 2017 to 2027. The market ... ... benefit you Read on to discover how you can exploit ...
(Date:2/17/2017)... 2017 Arvinas LLC, a private biotechnology company ... degradation, today announced the presentation of new preclinical data ... poster session at the American Society of Clinical Oncology ... Orlando, FL. "The new ... the potential of PROTACs to drive durable and robust ...
(Date:2/17/2017)... and Markets has announced the addition of the "Pharmaceutical Contract Manufacturing ... ... the US, Canada , Japan , ... of World. Annual estimates and forecasts are provided for the period 2015 ... Market data and analytics are derived from primary and secondary research. ...
Breaking Medicine Technology: